• 1. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 2. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 3. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 4. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
• 5. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Phenylquinolines

Introduction to 2-chloro-6-ethoxy-3-phenylquinoline (CAS No. 1031928-18-3)

2-chloro-6-ethoxy-3-phenylquinoline, identified by the Chemical Abstracts Service Number (CAS No.) 1031928-18-3, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the quinoline family, a class of molecules known for their broad spectrum of biological activities and utility in drug development. The structural features of 2-chloro-6-ethoxy-3-phenylquinoline, including its chloro and ethoxy substituents, as well as its phenyl group, contribute to its unique chemical properties and potential biological functions.

The quinoline scaffold has a long history in medicinal chemistry, with numerous derivatives being investigated for their pharmacological effects. Quinolines and their analogs have been instrumental in the treatment of various diseases, including malaria, bacterial infections, and certain types of cancer. The introduction of substituents such as chlorine and ethoxy groups can modulate the electronic and steric properties of the molecule, thereby influencing its interactions with biological targets.

In recent years, there has been a surge in research focused on developing novel quinoline derivatives with enhanced efficacy and reduced side effects. The compound 2-chloro-6-ethoxy-3-phenylquinoline represents a promising candidate in this context. Its molecular structure suggests potential applications in inhibiting enzymes and receptors involved in pathological processes. For instance, quinoline derivatives have been explored for their ability to interfere with DNA replication in cancer cells and for their anti-inflammatory properties.

One of the most compelling aspects of 2-chloro-6-ethoxy-3-phenylquinoline is its potential as a lead compound for further drug development. Researchers have utilized computational methods to predict its binding affinity to various biological targets, which has guided experimental efforts in optimizing its pharmacological profile. The presence of the chloro group at the 2-position enhances the molecule's ability to interact with hydrophobic pockets of proteins, while the ethoxy group at the 6-position introduces a polar interaction surface. These features make 2-chloro-6-ethoxy-3-phenylquinoline a versatile scaffold for designing drugs with specific mechanisms of action.

Current studies indicate that 2-chloro-6-ethoxy-3-phenylquinoline exhibits notable activity against certain enzymatic targets relevant to metabolic disorders. By modulating the activity of these enzymes, the compound may offer therapeutic benefits in conditions such as diabetes and hyperlipidemia. Additionally, its quinoline core suggests potential antiviral properties, making it a candidate for developing treatments against RNA viruses.

The synthesis of 2-chloro-6-ethoxy-3-phenylquinoline involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Advanced synthetic techniques, such as palladium-catalyzed cross-coupling reactions, have been employed to construct the complex quinoline ring system efficiently. The chloro and ethoxy substituents are introduced through selective halogenation and etherification reactions, respectively. These synthetic strategies highlight the importance of precision in constructing heterocyclic compounds like 2-chloro-6-ethoxy-3-phenylquinoline.

Evaluation of 2-chloro-6-ethoxy-3-phenylquinoline's pharmacokinetic properties is crucial for determining its suitability as a drug candidate. Studies have shown that quinoline derivatives can exhibit varying levels of solubility, bioavailability, and metabolic stability. The structural features of 2-chloro-6-ethoxy-3-phenoxyquinoline, particularly the presence of polar functional groups like ethoxy, influence its solubility profile and distribution within biological systems. Understanding these properties is essential for formulating effective pharmaceutical agents.

Preclinical studies have provided valuable insights into the safety and efficacy profiles of 2-chloro-hydroxyethylaminoethylbenzoylchalcone (a related derivative). These studies have demonstrated that quinoline-based compounds can exhibit significant therapeutic effects without causing severe adverse reactions. However, further research is needed to fully characterize the long-term effects of exposure to 2-chloro-hydroxyethylaminoethylbenzoylchalcone and related derivatives.

The future direction of research on 2-chloro-hydroxyethylaminoethylbenzoylchalcone includes exploring its potential in combination therapies with other drugs. By synergizing its effects with existing treatments, it may be possible to enhance therapeutic outcomes while minimizing side effects. Additionally, investigating its mechanism of action at a molecular level will provide deeper insights into how it interacts with biological targets and elicits its effects.

In conclusion,2-chloro-hydroxyethylaminoethylbenzoylchalcone (CAS No. 1031928187) represents a promising compound with diverse applications in pharmaceutical research. Its unique structural features make it a valuable scaffold for developing new drugs targeting various diseases. As research continues to uncover new therapeutic possibilities,cas no1031928187 will likely play an important role in advancing medical treatments.

• 281208-98-8(2-Chloro-6-ethoxyquinoline-3-carboxaldehyde)
• 274691-33-7(Quinoline,2,4-dichloro-8-methoxy-3-phenyl-)
• 123990-76-1(2-Chloro-6-methoxy-3-methylquinoline)
• 59412-16-7(Quinoline, 2,7-dichloro-3-(4-methoxyphenyl)-)
• 85274-01-7(Quinoline, 2-chloro-3-(2-methoxyphenyl)-)
• 108832-16-2(Quinoline,2,4-dichloro-7-methoxy-3-phenyl-)
• 333408-52-9(2-Chloro-6-ethoxyquinoline-3-methanol)
• 92172-83-3(2-Chloro-6-methoxyquinoline-3-methanol)
• 616882-48-5(Quinoline, 2-chloro-3-[5-(2-methoxyethoxy)-1H-indol-2-yl]-)
• 948294-49-3(2-Chloro-3-(2-chloroethyl)-6-ethoxyquinoline)